RICHMOND, Va., May 1, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the publication of a study "Monthly Buprenorphine Depot Injection (SUBLOCADE) for Opioid Use Disorder During ...

The Food & Drug Administration (FDA) announced its approval of an injectable form of buprenorphine (brand name: Sublocade), a medication used to treat opiate addiction. Sublocade releases a steady ...

A magnifying glass. It indicates, "Click to perform a search". A magnifying glass. It indicates, "Click to perform a search". Health Canada Grants Priority Review Designation for SUBLOCADE™ SLOUGH, ...

Rates of non-fatal overdose events following SUBLOCADE treatment was lower compared to daily opioid agonist therapy. Data published in the Journal of Addition Medicine RICHMOND, Va., Sept. 26, 2023 ...

Sublocade should be used as part of a complete treatment program that includes counseling and psychosocial support. Indivior announced that the Food and Drug Administration (FDA) has approved ...

The CEO highlighted that 2024 ended with SUBLOCADE achieving 20% net revenue growth despite challenges, including competition in the U.S. long-acting injectable (LAI) market and the discontinuation of ...

Please provide your email address to receive an email when new articles are posted on . New data show that rapid initiation with once-monthly Sublocade significantly improved treatment retention vs.

Please provide your email address to receive an email when new articles are posted on . The FDA approved label changes that include a rapid initiation protocol and alternative injection sites. The ...

SLOUGH, England and RICHMOND, Va., April 16, 2020 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced the publication of long-term safety data for SUBLOCADE® (buprenorphine extended-release) ...

(Reuters) - Indivior Plc cut its expectations for revenue from injectable opioid addiction drug Sublocade on Wednesday and said it had "substantially underestimated" the delay in getting the drug to ...